Glatiramer in the treatment of multiple sclerosis.
Multiple sclerosis (MS) is a disease of the central nervous system with both an inflammatory and degenerative component. The disease primarily affects young adults and results in significant physical and cognitive disability. Several disease-modifying agents are currently used in the management of multiple sclerosis. Glatiramer acetate (GA, Copaxone, co-polymer 1) is a disease-modifying agent approved for the treatment of relapsing remitting multiple sclerosis. Apart from its unique mode of action, there is evidence pointing toward a possible neuroprotective role. This review will critically discuss GA's potential mechanisms of action, the results of clinical trials, safety profile, and future directions of treatment.
Rizvi
Syed A
SA
Department of Clinical Neurosciences, Brown Medical School, Rhode Island Hospital, Providence, RI 02905, USA. srizvi@lifespan.org
Kim
Edward
E
Moodie
Jennifer
J
D002986:Clinical Trials as Topic; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D018448:Models, Immunological; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects; D055502:Secondary Prevention
D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents; D010455:Peptides; D000068717:Glatiramer Acetate
N Engl J Med. 1987 Aug 13;317(7):408-14
3302705
Neurology. 1991 Apr;41(4):533-9
2011253
Nature. 1992 Dec 24-31;360(6406):753-5
1281520
Neurology. 1995 Jul;45(7):1268-76
7617181
Science. 1995 Oct 27;270(5236):593-8
7570017
Annu Rev Neurosci. 1996;19:289-317
8833445
Nature. 1997 Jan 30;385(6615):391, 393
9009184
Nat Med. 1997 Jul;3(7):765-70
9212104
N Engl J Med. 1998 Jan 29;338(5):278-85
9445407
Neurology. 1998 Apr;50(4):1127-33
9566406
AJNR Am J Neuroradiol. 1998 Apr;19(4):675-83
9576653
J Neuroimmunol. 1998 Dec 1;92(1-2):113-21
9916886
Neurology. 2004 Dec 14;63(11 Suppl 5):S3-11
15596734
J Autoimmun. 2005 Mar;24(2):119-24
15829404
Neurology. 2005 Apr 26;64(8):1481-2
15851756
J Neuroimmunol. 2005 Oct;167(1-2):215-8
16083971
N Engl J Med. 2006 Mar 2;354(9):924-33
16510746
Mult Scler. 2006 Jun;12(3):309-20
16764344
Neurology. 2000 Feb 22;54(4):813-7
10690968
J Clin Invest. 2000 Apr;105(7):967-76
10749576
Ann Neurol. 2001 Mar;49(3):290-7
11261502
J Neuroimmunol. 2001 Apr 2;115(1-2):152-60
11282165
Neurology. 2001 Mar 27;56(6):702-8
11288751
Mult Scler. 2001 Feb;7(1):33-41
11321192
Brain. 2001 Sep;124(Pt 9):1803-12
11522582
Neurology. 2001 Aug 28;57(4):731-3
11524494
Nat Immunol. 2001 Sep;2(9):785-8
11526386
Mult Scler. 2001 Aug;7(4):209-19
11548979
Mult Scler. 2001 Dec;7(6):349-53
11795454
Clin Neuropharmacol. 2002 Jan-Feb;25(1):11-5
11852290
J Neuroimmunol. 2002 Feb;123(1-2):188-92
11880163
Neurology. 2002 Apr 23;58(8 Suppl 4):S3-9
11971121
Neurology. 2002 Sep 24;59(6):802-8
12349849
Brain. 2002 Nov;125(Pt 11):2381-91
12390966
Neurology. 2002 Oct 22;59(8):1284-6
12391370
Ann Neurol. 2003 Mar;53(3):292-304
12601697
Mult Scler. 2003 Feb;9(1):16-20
12617262
Trends Pharmacol Sci. 2003 Mar;24(3):131-8
12628358
Mult Scler. 2003 Aug;9(4):349-55
12926839
Eur J Neurol. 2003 Nov;10(6):671-6
14641512
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157-62
14614135
Cochrane Database Syst Rev. 2004;(1):CD004678
14974077
Expert Opin Pharmacother. 2004 Apr;5(4):875-91
15102570
Neurology. 2004 Apr 27;62(8):1432-4
15111692
Mult Scler. 2004 Jun;10 Suppl 1:S65-71; discussion S71-2
15218813
Eur J Immunol. 1971 Aug;1(4):242-8
5157960
J Neurol Sci. 1977 Apr;31(3):433-8
845620
Ann Neurol. 1982 Mar;11(3):317-9
7092185